Skip to main navigation Skip to search Skip to main content

Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma

  • Jared J. Gartner
  • , Stephen C. J. Parker
  • , Todd D. Prickett
  • , Ken Dutton-Regester
  • , Michael L. Stitzel
  • , Jimmy C. Lin
  • , Sean Davis
  • , Vijaya L. Simhadri
  • , Sujata Jha
  • , Nobuko Katagiri
  • , Valer Gotea
  • , Jamie K. Teer
  • , Xiaomu Wei
  • , Mario A. Morken
  • , Umesh K. Bhanot
  • , Guo Chen
  • , Laura L. Elnitski
  • , Michael A. Davies
  • , Jeffrey E. Gershenwald
  • , Hannah Carter
  • Rachel Karchin, William Robinson, Steven Robinson, Steven A. Rosenberg, Francis S. Collins, Giovanni Parmigiani, Anton A Komar, Chava Kimchi-Sarfaty, Nicholas K. Hayward, Elliott H. Margulies, Yardena Samuels
  • National Human Genome Research Institute (NHGRI)
  • Queensland Institute of Medical Research
  • Washington University School of Medicine in St. Louis
  • National Cancer Institute (NCI)
  • Food and Drug Administration
  • Cleveland State University
  • Memorial Sloan-Kettering Cancer Center
  • University of Texas MD Anderson Cancer Center
  • Johns Hopkins University
  • University of Colorado School of Medicine
  • Dana Farber Cancer Institute
  • Harvard School of Public Health
  • Illumina United Kingdom
  • Weizmann Institute of Science Israel

Research output: Contribution to journalArticlepeer-review

154 Scopus citations

Abstract

Synonymous mutations, which do not alter the protein sequence, have been shown to affect protein function [Sauna ZE, Kimchi- Sarfaty C (2011) Nat Rev Genet 12(10):683-691]. However, synonymous mutations are rarely investigated in the cancer genomics field. We used whole-genome and -exome sequencing to identify somatic mutations in 29 melanoma samples. Validation of one synonymous somatic mutation in BCL2L12 in 285 samples identified 12 cases that harbored the recurrent F17F mutation. This mutation led to increased BCL2L12 mRNA and protein levels because of differential targeting of WT and mutant BCL2L12 by hsa-miR- 671-5p. Protein made from mutant BCL2L12 transcript bound p53, inhibited UV-induced apoptosis more efficiently than WT BCL2L12, and reduced endogenous p53 target gene transcription. This report shows selection of a recurrent somatic synonymous mutation in cancer. Our data indicate that silent alterations have a role to play in human cancer, emphasizing the importance of their investigation in future cancer genome studies.
Original languageEnglish
Pages (from-to)13481-13486
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number33
DOIs
StatePublished - Aug 13 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this